Showing 1471-1480 of 1717 results for "".
- AAN Practice Advisory on PFO Closure After Strokehttps://practicalneurology.com/news/aan-practice-advisory-on-pfo-closure-after-stroke/2469245/The American Academy of Neurology (AAN) has released a practice advisory concluding that poststroke surgical closure of a patent foramen ovale (PFO) may be recommended for some individuals. This practice advisory is endorsed by American Heart Association/American Stroke Association, the Society f
- Stroke Care Emergency Guidance During COVID-19 Pandemichttps://practicalneurology.com/news/stroke-care-emergency-guidance-during-covid-19-pandemic/2469213/The American Heart Association/American Stroke Association’s Stroke Council Leadership has released the “Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic”. The Stroke Council Leadership recommends that US stroke centers: • 
- Advances Reported in Search for Blood Markers for Alzheimer’s Disease and Other Dementiashttps://practicalneurology.com/news/advances-reported-in-search-for-blood-markers-for-alzheimers-disease-and-other-dementias/2468962/At the Alzheimer’s Association International Conference in Los Angeles, July 14-18, 2019, results from a study published in Nature were presented describing measures of blood amyloid isoforms associated with established Alzheimer’s disease (AD) markers. Analysis of 201
- Sleep-Disordered Breathing and Sleep Disruption Accelerate Aginghttps://practicalneurology.com/news/sleep-disordered-breathing-and-sleep-disruption-accelerate-aging/2468927/Each standard deviation increase in the apnea-hypoxia index (AHI) was associated with a 215-day (7 months) acceleration of epigenetic aging. Similarly, each standard deviation increase in the arousal index was associated with a 321-day acceleration in epigenetic aging. Epigenetic age acceleration
- Solriamfetol Improves Cognition in Individuals with Excessive Daytime Sleepiness Due to Obstructive Sleep Apneahttps://practicalneurology.com/news/solriamfetol-improves-cognition-in-individuals-with-excessive-daytime-sleepiness-due-to-obstructive-sleep-apnea/2470038/In the SHARP (NCT04789174) study, individuals with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) who were treated with solriamfetol (Sunosi; Axsome Therapeutics,
- Heart Function May Affect Cognitive Skills at Middle Agehttps://practicalneurology.com/news/heart-function-may-affect-cognitive-skills-at-middle-age/2469807/In a study published in an Neurology, changes in the structure and diastolic function of the heart between early adulthood and middle age may be associated with a decline in thinking and memory skil
- Perivascular Space Disease May Increase Dementia Riskhttps://practicalneurology.com/news/perivascular-space-disease-may-increase-dementia-risk/2469484/According to a new study published in Neurology, enlarged perivascular spaces in the brain may be associated with a higher likelihood of develop cognitive problems and dementia over time.
- AHA Issues Guidance on Preventing and Treating Maternal Stroke in Scientific Statementhttps://practicalneurology.com/news/aha-issues-guidance-on-preventing-and-treating-maternal-stroke-in-scientific-statement/2485566/The American Heart Association (AHA) has released a scientific statement providing comprehensive, consensus-based guidance on the prevention, acute management, and care of maternal stroke during pregnancy and the postpartum period. The statement, endorsed by the American College of Obstetricians
- Application Submitted to Begin Clinical Development of an Oral Therapy for Agitation in Alzheimer’shttps://practicalneurology.com/news/application-submitted-to-begin-clinical-development-of-an-oral-therapy-for-agitation-in-alzheimers/2485311/Mandara Biopharma (Boulder, CO) has filed an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to initiate clinical development of an oral dronabinol formulation for the treatment of agitation associated with Alzheimer disease (AD). The investigational
- Small Molecule Kinase Inhibitor Slowed Clinical Progression in People with Dementia with Lewy Bodieshttps://practicalneurology.com/news/small-molecule-kinase-inhibitor-associated-with-progression-in-people-with-dementia-with-lewy-bodies/2484935/Treatment with neflamapimod (CervoMed, Boston, MA) —an investigational, orally administered small molecule kinase inhibitor—was associated with significant improvements in clinical and biomarker outcomes in people with dementia with Lewy bodies (DLB), according to findings from the extension-phas